New research reveals that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Findings released in a major health publication shows that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Users using such drugs must be aware of the risk of fast rebound weight gain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain suggests a reversion to original weight within about a year and a half.
Comparing Approaches
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the effects of the injectable medications with conventional dieting.
The team note that people who lose weight through dieting typically have a less rapid weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Nutrition scientists believe the way of the jabs accounts for the amplified rebound.
The injections mimic a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating much more probable."
A Lifelong Issue?
Health authorities advise the injections for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, due to the significant potential of weight regain, the treatment might need to be life-long.
This view is supported by drug manufacturers, who say that the results "emphasize the long-term nature of excess weight," similar to managing conditions like hypertension.
Patient Experiences
People who have discontinued the jabs report a intense return of appetite.
"It felt as if a trigger that goes on and you're instantly starving," recalled an individual.
The struggle is compounded if users have not established lasting dietary or behavioural changes during treatment.
Widespread Use
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with demand being substantial.
- Adoption is more common among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, experts stress that while these medications are powerful agents for shedding pounds, they are not a standalone cure and lasting health benefits relies on ongoing behavioural management.
